Trial Outcomes & Findings for Acceptability of the NuvaRing Among Students (NCT NCT00635570)

NCT ID: NCT00635570

Last Updated: 2021-02-03

Results Overview

"Perfect use" was defined as reporting never missing a pill or never removing the contraceptive vaginal ring for more than 2 hours during days 1-21 of all three monthly cycles

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

273 participants

Primary outcome timeframe

For the first 3 months

Results posted on

2021-02-03

Participant Flow

We recruited 276 participants between March 2006 and December 2008 at two Midwest university-based sites through passive (online and subway advertisements) and active recruitment (referrals from local clinics and health care providers).

We screened 276 participants, of whom 273 were eligible because 3 of them did not meet inclusion criteria.

Participant milestones

Participant milestones
Measure
Contraceptive Vaginal Ring
Contraceptive vaginal ring (NuvaRing)
Oral Contraceptive Pill
Oral contraceptive pill (Ortho Tri-Cyclen Lo)
Overall Study
STARTED
136
137
Overall Study
COMPLETED
121
126
Overall Study
NOT COMPLETED
15
11

Reasons for withdrawal

Reasons for withdrawal
Measure
Contraceptive Vaginal Ring
Contraceptive vaginal ring (NuvaRing)
Oral Contraceptive Pill
Oral contraceptive pill (Ortho Tri-Cyclen Lo)
Overall Study
Lost to Follow-up
8
8
Overall Study
Withdrawal by Subject
1
1
Overall Study
Adverse Event
2
0
Overall Study
Physician Decision
1
0
Overall Study
Did not complete survey
2
1
Overall Study
Early termination(No sexual activity)
1
1

Baseline Characteristics

Acceptability of the NuvaRing Among Students

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Contraceptive Vaginal Ring
n=136 Participants
Contraceptive vaginal ring (NuvaRing)
Oral Contraceptive Pill
n=137 Participants
Oral contraceptive pill (Ortho Tri-Cyclen Lo)
Total
n=273 Participants
Total of all reporting groups
Age, Continuous
22.3 years
n=5 Participants
22 years
n=7 Participants
22.1 years
n=5 Participants
Sex: Female, Male
Female
136 Participants
n=5 Participants
137 Participants
n=7 Participants
273 Participants
n=5 Participants
Sex: Female, Male
Male
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race/Ethnicity, Customized
Hispanic
24 participants
n=5 Participants
20 participants
n=7 Participants
44 participants
n=5 Participants
Race/Ethnicity, Customized
Non-Hispanic White
66 participants
n=5 Participants
59 participants
n=7 Participants
125 participants
n=5 Participants
Race/Ethnicity, Customized
Non-Hispanic African American
23 participants
n=5 Participants
28 participants
n=7 Participants
51 participants
n=5 Participants
Race/Ethnicity, Customized
Non-Hispanic Asian
13 participants
n=5 Participants
15 participants
n=7 Participants
28 participants
n=5 Participants
Race/Ethnicity, Customized
Non-Hispanic other/multiple
10 participants
n=5 Participants
14 participants
n=7 Participants
24 participants
n=5 Participants
Race/Ethnicity, Customized
Missing
0 participants
n=5 Participants
1 participants
n=7 Participants
1 participants
n=5 Participants
Living arrangement
Alone
35 participants
n=5 Participants
32 participants
n=7 Participants
67 participants
n=5 Participants
Living arrangement
With partner
16 participants
n=5 Participants
11 participants
n=7 Participants
27 participants
n=5 Participants
Living arrangement
With others, not partner
54 participants
n=5 Participants
63 participants
n=7 Participants
117 participants
n=5 Participants
Living arrangement
With family
30 participants
n=5 Participants
31 participants
n=7 Participants
61 participants
n=5 Participants
Living arrangement
Missing
1 participants
n=5 Participants
0 participants
n=7 Participants
1 participants
n=5 Participants
Location
Dorm
29 participants
n=5 Participants
34 participants
n=7 Participants
63 participants
n=5 Participants
Location
Off campus
106 participants
n=5 Participants
103 participants
n=7 Participants
209 participants
n=5 Participants
Location
Missing
1 participants
n=5 Participants
0 participants
n=7 Participants
1 participants
n=5 Participants
Religious preference
Catholic
33 participants
n=5 Participants
36 participants
n=7 Participants
69 participants
n=5 Participants
Religious preference
Protestant
19 participants
n=5 Participants
22 participants
n=7 Participants
41 participants
n=5 Participants
Religious preference
Baptist
11 participants
n=5 Participants
13 participants
n=7 Participants
24 participants
n=5 Participants
Religious preference
Other
18 participants
n=5 Participants
27 participants
n=7 Participants
45 participants
n=5 Participants
Religious preference
None
54 participants
n=5 Participants
37 participants
n=7 Participants
91 participants
n=5 Participants
Religious preference
Missing
1 participants
n=5 Participants
2 participants
n=7 Participants
3 participants
n=5 Participants
Relationship status
Living with a partner in a committed relationship
19 participants
n=5 Participants
15 participants
n=7 Participants
34 participants
n=5 Participants
Relationship status
A committed relationship, not living w/ a partner
60 participants
n=5 Participants
79 participants
n=7 Participants
139 participants
n=5 Participants
Relationship status
Not in a committed relationship
57 participants
n=5 Participants
41 participants
n=7 Participants
98 participants
n=5 Participants
Relationship status
Missing
0 participants
n=5 Participants
2 participants
n=7 Participants
2 participants
n=5 Participants
Age at sexual debut
17.4 Years
n=5 Participants
17.8 Years
n=7 Participants
17.6 Years
n=5 Participants
Vaginal sex in the past month
Yes
100 participants
n=5 Participants
102 participants
n=7 Participants
202 participants
n=5 Participants
Vaginal sex in the past month
No
25 participants
n=5 Participants
25 participants
n=7 Participants
50 participants
n=5 Participants
Frequency of sex in current or most recent relationship
None
4 participants
n=5 Participants
2 participants
n=7 Participants
6 participants
n=5 Participants
Frequency of sex in current or most recent relationship
Once a month or less
15 participants
n=5 Participants
11 participants
n=7 Participants
26 participants
n=5 Participants
Frequency of sex in current or most recent relationship
2 or 3 times a month
19 participants
n=5 Participants
18 participants
n=7 Participants
37 participants
n=5 Participants
Frequency of sex in current or most recent relationship
Approximately once a week
25 participants
n=5 Participants
21 participants
n=7 Participants
46 participants
n=5 Participants
Frequency of sex in current or most recent relationship
2 or 3 times a week
28 participants
n=5 Participants
37 participants
n=7 Participants
65 participants
n=5 Participants
Frequency of sex in current or most recent relationship
More than 3 times a week
34 participants
n=5 Participants
36 participants
n=7 Participants
70 participants
n=5 Participants
Frequency of sex in current or most recent relationship
Missing
0 participants
n=5 Participants
2 participants
n=7 Participants
2 participants
n=5 Participants
Pregnant ever
Yes
24 participants
n=5 Participants
12 participants
n=7 Participants
36 participants
n=5 Participants
Pregnant ever
No
101 participants
n=5 Participants
115 participants
n=7 Participants
216 participants
n=5 Participants

PRIMARY outcome

Timeframe: For the first 3 months

"Perfect use" was defined as reporting never missing a pill or never removing the contraceptive vaginal ring for more than 2 hours during days 1-21 of all three monthly cycles

Outcome measures

Outcome measures
Measure
Contraceptive Vaginal Ring
n=136 Participants
Contraceptive vaginal ring (NuvaRing)
Oral Contraceptive Pill
n=137 Participants
Oral contraceptive pill (Ortho Tri-Cyclen Lo)
Adherence Rate (Rate of Perfect Method Use)
57 Percentage of Participants
45 Percentage of Participants

SECONDARY outcome

Timeframe: at 3 months

Population: 26 participants, 15 out of the contraceptive vaginal ring group and 11 out of the oral contraceptive pill group were excluded. (See the participant flow chart)

Outcome measures

Outcome measures
Measure
Contraceptive Vaginal Ring
n=121 Participants
Contraceptive vaginal ring (NuvaRing)
Oral Contraceptive Pill
n=126 Participants
Oral contraceptive pill (Ortho Tri-Cyclen Lo)
Satisfaction Rate
Satisfaction - Yes
68 Percentage of Participants
71 Percentage of Participants
Satisfaction Rate
Satisfaction - No
23 Percentage of Participants
25 Percentage of Participants
Satisfaction Rate
Missing
9 Percentage of Participants
4 Percentage of Participants

SECONDARY outcome

Timeframe: at 3 months

Population: 26 participants, 15 out of the contraceptive vaginal ring group and 11 out of the oral contraceptive pill group were excluded. (See the participant flow chart)

Rate of intention to continue the contraceptive method at 3 months

Outcome measures

Outcome measures
Measure
Contraceptive Vaginal Ring
n=121 Participants
Contraceptive vaginal ring (NuvaRing)
Oral Contraceptive Pill
n=126 Participants
Oral contraceptive pill (Ortho Tri-Cyclen Lo)
Continuation Rate
Continuation - No
52 Percentage of Participants
48 Percentage of Participants
Continuation Rate
Missing
5 Percentage of Participants
0 Percentage of Participants
Continuation Rate
Continuation - Yes
43 Percentage of Participants
52 Percentage of Participants

POST_HOC outcome

Timeframe: at 6 month (3 month after the end of the study period)

Population: At 6 months, four from the contraceptive vaginal ring group and three from the oral contraceptive pill group did not complete the 6-month survey and thus were excluded from analysis.

Rate of intention to continue the contraceptive method at 6 months

Outcome measures

Outcome measures
Measure
Contraceptive Vaginal Ring
n=117 Participants
Contraceptive vaginal ring (NuvaRing)
Oral Contraceptive Pill
n=123 Participants
Oral contraceptive pill (Ortho Tri-Cyclen Lo)
Continuation Rate
Continuation - Yes
26 Percentage of Participants
29 Percentage of Participants
Continuation Rate
Continuation - No
72 Percentage of Participants
68 Percentage of Participants
Continuation Rate
Missing
2 Percentage of Participants
2 Percentage of Participants

Adverse Events

Contraceptive Vaginal Ring

Serious events: 0 serious events
Other events: 100 other events
Deaths: 0 deaths

Oral Contraceptive Pill

Serious events: 0 serious events
Other events: 105 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Contraceptive Vaginal Ring
n=136 participants at risk
Contraceptive vaginal ring (NuvaRing)
Oral Contraceptive Pill
n=137 participants at risk
Oral contraceptive pill (Ortho Tri-Cyclen Lo)
Gastrointestinal disorders
Bloating
53.7%
73/136 • 6 months
56.9%
78/137 • 6 months
Gastrointestinal disorders
Nausea
61.0%
83/136 • 6 months
50.4%
69/137 • 6 months
Investigations
Weight gain
11.8%
16/136 • 6 months
13.1%
18/137 • 6 months
Nervous system disorders
Headaches
68.4%
93/136 • 6 months
74.5%
102/137 • 6 months
Reproductive system and breast disorders
Breast swelling
52.2%
71/136 • 6 months
59.9%
82/137 • 6 months
Reproductive system and breast disorders
Irregular menstruation
10.3%
14/136 • 6 months
8.0%
11/137 • 6 months
Reproductive system and breast disorders
Vaginal discomfort
55.1%
75/136 • 6 months
42.3%
58/137 • 6 months
Reproductive system and breast disorders
Vaginal discharge
33.8%
46/136 • 6 months
10.9%
15/137 • 6 months

Additional Information

Melissa Gilliam

Department of Obstetrics and Gynecology, The University of Chicago

Phone: 773-834-0840

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place